Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Abstract 1241: Enhancing NK cell therapy for head and neck cancer within the solid tumor microenvironment using a B7H3-targeting tri-specific killer engager (TriKE)

Melissa Khaw, Nicholas A. Zorko, Carly Selleck, Laura Bendzick, Zachary Davis, Peter Hinderlie, Madison Shackelford, Ann Lu, James Lim, Naomi Fujioka, Margaret MacMillan, John Wagner, Martin Felices, Jeffrey S. Miller

Cancer Res (2024) 84 (6_Supplement): 1241.

https://doi.org/10.1158/1538-7445.AM2024-1241

Published: 22 March 2024

View article titled, Abstract 1241: Enhancing NK cell therapy for head and neck cancer within the solid tumor microenvironment using a B7H3-targeting tri-specific killer engager (TriKE)

Journal Articles

Abstract 1240: Enhancing NK cell function in the ‘cold’ tumor microenvironment of prostate cancer with a novel tri-specific killer engager

Shee Kwan Phung, Yvette Soignier, Nicholas Zorko, Rhett L. Waller, Josh Walker, Trygve Nelson, Carly Selleck, Laura Bendzick, Philippa Kennedy, Jeffrey S. Miller, Martin Felices

Cancer Res (2024) 84 (6_Supplement): 1240.

https://doi.org/10.1158/1538-7445.AM2024-1240

Published: 22 March 2024

View article titled, Abstract 1240: Enhancing NK cell function in the ‘cold’ tumor microenvironment of prostate cancer with a novel tri-specific killer engager

Journal Articles

Abstract B040: Trispecific killer engagers against IGF1R and fetal form of insulin receptor induce human natural killer cell mediated killing of hormone receptor positive breast cancer in vitro and in vivo

Courtney Baar, Emily Chiu, Yvette Soignier, Behiye Kodal, Jeffrey S Miller, Martin Felices, Deepali Sachdev

Cancer Res (2024) 84 (3_Supplement_1): B040.

https://doi.org/10.1158/1538-7445.ADVBC23-B040

Published: 01 February 2024

View article titled, Abstract B040: Trispecific killer engagers against IGF1R and fetal form of insulin receptor induce human natural killer cell mediated killing of hormone receptor positive breast cancer in vitro and in vivo

Journal Articles

Abstract 2761: FT573: Preclinical development of multiplexed-engineered iPSC-derived NK cells expressing a novel camelid nanobody chimeric antigen receptor (CAR) targeting pan-cancer antigen B7-H3

Nicholas Zorko, Frank Cichocki, John Goulding, Bryan Hancock, Robert Blum, Mochtar Pribadi, Bjoern Gaertner, Tom Lee, Martin Felices, Ryan Bjordahl, Bahram Valamehr, Jeffrey S. Miller

Cancer Res (2022) 82 (12_Supplement): 2761.

https://doi.org/10.1158/1538-7445.AM2022-2761

Published: 15 June 2022

View article titled, Abstract 2761: FT573: Preclinical development of multiplexed-engineered iPSC-derived NK cells expressing a novel camelid nanobody chimeric antigen receptor (CAR) targeting pan-cancer antigen B7-H3

Journal Articles

Abstract 2878: Mediating NK cell function against solid tumors, via targeting of tumor stroma, using a TEM8-targeting Tri-specific Killer Engager (TriKE®)

Martin Felices, Michael Kaminski, Peter Hinderlie, Rachel Hopps, Laura Bendzick, Melissa Geller, Jeffrey S. Miller

Cancer Res (2022) 82 (12_Supplement): 2878.

https://doi.org/10.1158/1538-7445.AM2022-2878

Published: 15 June 2022

View article titled, Abstract 2878: Mediating NK cell function against solid tumors, via targeting of tumor stroma, using a TEM8-targeting Tri-specific Killer Engager (TriKE®)

Journal Articles

Abstract 3435: GTB-5550 (cam16-IL15-camB7H3) trispecific killer engager (TriKE®) drives natural killer cell activation and antibody dependent cellular cytotoxicity against head and neck squamous cell carcinomas

Melissa Khaw, Zachary Davis, Nicholas Zorko, Greg Berk, Gavin Choy, Margaret MacMillan, Martin Felices, Jeffrey S. Miller

Cancer Res (2022) 82 (12_Supplement): 3435.

https://doi.org/10.1158/1538-7445.AM2022-3435

Published: 15 June 2022

View article titled, Abstract 3435: GTB-5550 (cam16-IL15-camB7H3) trispecific killer engager (TriKE®) drives natural killer cell activation and antibody dependent cellular cytotoxicity against head and neck squamous cell carcinomas

Journal Articles

Abstract 1550: FT576 path to first-of-kind clinical trial: translation of a versatile multi-antigen specific off-the-shelf NK cell for treatment of multiple myeloma

Jode P. Goodridge, Ryan Bjordahl, Sajid Mahmood, John Reiser, Svetlana Gaidarova, Robert Blum, Frank Cichocki, Hui-yi Chu, Greg Bonello, Tom Lee, Brian Groff, Miguel Meza, Thomas Daley, Yu-waye Chu, Bruce Walcheck, Karl-Johan Malmberg, Jeffrey S. Miller, Armin Rehm, Bahram Valamehr

Cancer Res (2021) 81 (13_Supplement): 1550.

https://doi.org/10.1158/1538-7445.AM2021-1550

Published: 01 July 2021

View article titled, Abstract 1550: FT576 path to first-of-kind clinical trial: translation of a versatile multi-antigen specific off-the-shelf NK cell for treatment of multiple myeloma

Journal Articles

Abstract 1539: Development of off-the-shelf B7H3 chimeric antigen receptor NK cell therapeutic with broad applicability across many solid tumors

Ryan Bjordahl, John Goulding, Hui-Yi Chu, Frank Cichocki, Nicholas Zorko, Zachary Davis, Martin Felices, Alex Garcia, Svetlana Gaidarova, Wen-I Yeh, Tom T. Lee, Jeffrey S. Miller, Bahram Valamehr

Cancer Res (2021) 81 (13_Supplement): 1539.

https://doi.org/10.1158/1538-7445.AM2021-1539

Published: 01 July 2021

View article titled, Abstract 1539: Development of off-the-shelf B7H3 chimeric antigen receptor NK cell therapeutic with broad applicability across many solid tumors

Journal Articles

Abstract 2216: Combinational strategy targeting B cell malignancy using iPSC engineered CAR-NK (FT596) and CAR-T cell (FT819) platforms with therapeutic antibody to achieve an effective deep and durable response

Cancer Res (2020) 80 (16_Supplement): 2216.

https://doi.org/10.1158/1538-7445.AM2020-2216

Published: 15 August 2020

View article titled, Abstract 2216: Combinational strategy targeting B cell malignancy using iPSC engineered CAR-NK (FT596) and CAR-T cell (FT819) platforms with therapeutic antibody to achieve an effective deep and durable response

Journal Articles

Abstract P5-04-11: Targeting hormone receptor positive breast cancer for immune destruction by natural killer cells

Emily Chiu, Ivy R Johnson, Jeffrey S Miller, Martin Felices, Deepali Sachdev

Cancer Res (2020) 80 (4_Supplement): P5-04-11.

https://doi.org/10.1158/1538-7445.SABCS19-P5-04-11

Published: 15 February 2020

View article titled, Abstract P5-04-11: Targeting hormone receptor positive breast cancer for immune destruction by natural killer cells

Journal Articles

Abstract 614: Cytomegalovirus (CMV) reactivation and patient survival in head and neck cancer

Heather H. Nelson, Jeffrey S. Miller, DeVon Hunter-Schlichting, Rondi A. Butler, Karl T. Kelsey

Cancer Res (2019) 79 (13_Supplement): 614.

https://doi.org/10.1158/1538-7445.AM2019-614

Published: 01 July 2019

View article titled, Abstract 614: Cytomegalovirus (CMV) reactivation and patient survival in head and neck cancer

Journal Articles

Abstract CT079: A Phase I study of PNK-007, allogeneic, off the shelf NK cell in relapsed/refractory AML (NCT02781467)

Sarah Cooley, Parameswaran Hari, James McCloskey, Michael Byrne, Eunice Wang, Mohamad Hussein, Erica Giarritta, Xiaokui Zhang, Robert Hariri, Jeffrey S. Miller

Cancer Res (2019) 79 (13_Supplement): CT079.

https://doi.org/10.1158/1538-7445.AM2019-CT079

Published: 01 July 2019

View article titled, Abstract CT079: A Phase I study of PNK-007, allogeneic, off the shelf NK cell in relapsed/refractory AML (NCT02781467)

Journal Articles

Abstract LB-070: Immune monitoring of PNK-007, an allogeneic, off the shelf NK cell in a Phase I study of acute myeloid leukemia

William van der Touw, Lin Kang, Julie M. Curtsinger, Vanessa Voskinarian-Berse, Bhavani Stout, Mohamad Hussein, Sarah A. Cooley, Jeffrey S. Miller, Robert Hariri, Xiaokui Zhang

Cancer Res (2019) 79 (13_Supplement): LB-070.

https://doi.org/10.1158/1538-7445.AM2019-LB-070

Published: 01 July 2019

View article titled, Abstract LB-070: Immune monitoring of PNK-007, an allogeneic, off the shelf NK cell in a Phase I study of acute myeloid leukemia

Journal Articles

Abstract 4939: Driving natural killer cell antigen-specific targeting of cancer via next generation trivalent molecules

Martin Felices, Behiye Kodal, Alexander J. Lenvik, Brianna Ettestad, Laura Bendzick, Caitlin Ryan, Dawn K. Schirm, Ron McElmurry, Craig E. Eckfeldt, Melissa A. Geller, Todd R. Lenvik, Daniel A. Vallera, Jeffrey S. Miller

Cancer Res (2018) 78 (13_Supplement): 4939.

https://doi.org/10.1158/1538-7445.AM2018-4939

Published: 01 July 2018

View article titled, Abstract 4939: Driving natural killer cell antigen-specific targeting of cancer via next generation trivalent molecules

Journal Articles

GSK3 Inhibition Drives Maturation of NK Cells and Enhances Their Antitumor Activity

Cancer Res (2017) 77 (20): 5664–5675.

https://doi.org/10.1158/0008-5472.CAN-17-0799

Published: 15 October 2017

View article titled, GSK3 Inhibition Drives Maturation of NK Cells and Enhances Their Antitumor Activity

Includes: Supplementary data

Journal Articles

Abstract 3755: Renewable and genetically engineered natural killer cells for off-the-shelf adoptive cellular immunotherapy

Cancer Res (2017) 77 (13_Supplement): 3755.

https://doi.org/10.1158/1538-7445.AM2017-3755

Published: 01 July 2017

View article titled, Abstract 3755: Renewable and genetically engineered natural killer cells for off-the-shelf adoptive cellular immunotherapy

Journal Articles

Abstract 3752: FATE-NK100: A novel NK cell-mediated cancer therapy

Frank Cichocki, Barham Valamehr, Ryan Bjordahl, Bin Zhang, Dhifaf Sarhan, Sarah Cooley, Bruce Blazar, Betsy Rezner, Paul Rogers, Chad Green, Stewart Abbot, Daniel Shoemaker, Scott Wolchko, Jeffrey S. Miller

Cancer Res (2017) 77 (13_Supplement): 3752.

https://doi.org/10.1158/1538-7445.AM2017-3752

Published: 01 July 2017

View article titled, Abstract 3752: FATE-NK100: A novel NK cell-mediated cancer therapy

Journal Articles

Adaptive NK Cells with Low TIGIT Expression Are Inherently Resistant to Myeloid-Derived Suppressor Cells

Dhifaf Sarhan, Frank Cichocki, Bin Zhang, Ashley Yingst, Stephen R. Spellman, Sarah Cooley, Michael R. Verneris, Bruce R. Blazar, Jeffrey S. Miller

Cancer Res (2016) 76 (19): 5696–5706.

https://doi.org/10.1158/0008-5472.CAN-16-0839

Published: 02 October 2016

View article titled, Adaptive NK Cells with Low TIGIT Expression Are Inherently Resistant to Myeloid-Derived Suppressor Cells

Includes: Supplementary data

Journal Articles

Abstract 1493: Improvement of the bispecific antibody ADCC platform by genetic insertion of IL-15 as a cross-linker to create NK cell reactive TriKEs

Daniel A. Vallera, Joerg U. Schmohl, Martin Felices, Jeffrey S. Miller

Cancer Res (2016) 76 (14_Supplement): 1493.

https://doi.org/10.1158/1538-7445.AM2016-1493

Published: 15 July 2016

View article titled, Abstract 1493: Improvement of the bispecific antibody ADCC platform by genetic insertion of IL-15 as a cross-linker to create NK cell reactive TriKEs

Journal Articles

Abstract 533: Dendritic cells are professional educators of Natural Killer cells

Andres Wiernik, Jeffrey S. Miller

Cancer Res (2012) 72 (8_Supplement): 533.

https://doi.org/10.1158/1538-7445.AM2012-533

Published: 15 April 2012

View article titled, Abstract 533: Dendritic cells are professional educators of Natural Killer cells

NARROW

Abstract 1241: Enhancing NK cell therapy for head and neck cancer within the solid tumor microenvironment using a B7H3-targeting tri-specific killer engager (TriKE)

Abstract 1240: Enhancing NK cell function in the ‘cold’ tumor microenvironment of prostate cancer with a novel tri-specific killer engager

Abstract B040: Trispecific killer engagers against IGF1R and fetal form of insulin receptor induce human natural killer cell mediated killing of hormone receptor positive breast cancer in vitro and in vivo

Abstract 2761: FT573: Preclinical development of multiplexed-engineered iPSC-derived NK cells expressing a novel camelid nanobody chimeric antigen receptor (CAR) targeting pan-cancer antigen B7-H3

Abstract 2878: Mediating NK cell function against solid tumors, via targeting of tumor stroma, using a TEM8-targeting Tri-specific Killer Engager (TriKE®)

Abstract 3435: GTB-5550 (cam16-IL15-camB7H3) trispecific killer engager (TriKE®) drives natural killer cell activation and antibody dependent cellular cytotoxicity against head and neck squamous cell carcinomas

Abstract 1550: FT576 path to first-of-kind clinical trial: translation of a versatile multi-antigen specific off-the-shelf NK cell for treatment of multiple myeloma

Abstract 1539: Development of off-the-shelf B7H3 chimeric antigen receptor NK cell therapeutic with broad applicability across many solid tumors

Abstract 2216: Combinational strategy targeting B cell malignancy using iPSC engineered CAR-NK (FT596) and CAR-T cell (FT819) platforms with therapeutic antibody to achieve an effective deep and durable response

Abstract P5-04-11: Targeting hormone receptor positive breast cancer for immune destruction by natural killer cells

Abstract 614: Cytomegalovirus (CMV) reactivation and patient survival in head and neck cancer

Abstract CT079: A Phase I study of PNK-007, allogeneic, off the shelf NK cell in relapsed/refractory AML (NCT02781467)

Abstract LB-070: Immune monitoring of PNK-007, an allogeneic, off the shelf NK cell in a Phase I study of acute myeloid leukemia

Abstract 4939: Driving natural killer cell antigen-specific targeting of cancer via next generation trivalent molecules

GSK3 Inhibition Drives Maturation of NK Cells and Enhances Their Antitumor Activity

Abstract 3755: Renewable and genetically engineered natural killer cells for off-the-shelf adoptive cellular immunotherapy

Abstract 3752: FATE-NK100: A novel NK cell-mediated cancer therapy

Adaptive NK Cells with Low TIGIT Expression Are Inherently Resistant to Myeloid-Derived Suppressor Cells

Abstract 1493: Improvement of the bispecific antibody ADCC platform by genetic insertion of IL-15 as a cross-linker to create NK cell reactive TriKEs

Abstract 533: Dendritic cells are professional educators of Natural Killer cells

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only